Teva Will Centralize Global Logistics for Clinical Trials in Spain

The Israeli company Teva announced the implementation throughout this year of new capabilities that will place its logistics center in Spain in a central position in the global distribution of investigational drugs for clinical trials. This operation entails the centralization in Zaragoza, where this center is located, of the global customer service.

Company sources explained that the management of storage, secondary packaging and distribution of research drugs has already been implemented, and that it is estimated that by the middle of this year the handling of trials will be included. Customer service services began this January and will include all countries in the coming months.

The company has not estimated any economic investment for this specific project, since, according to the same sources, they already had the structure and knowledge to carry it out.

The logistics center was created in 2009 and in these almost 15 years it has multiplied its production volume sevenfold. Today this plant has 600 workers, of the 900 who work for the company in Spain. Teva produces about 8.1 billion doses per year in a 56,000-square-meter facility.

Read more about Teva and find other important financial news from around the world with our companion app Born2Invest.

Teva suffered a decline in worldwide turnover that culminated in an ERE of 50 employees

In 2021, Teva’s Spanish subsidiary had a turnover of around 412 million euros in a global context of slowing turnover, which in 2022 fell by 6%, with global sales of almost $15 billion. Faced with this situation, the company executed an employment regulation file (ERE) that affected 50 employees, most of them in Madrid.

Added to the decrease in turnover is the $225 million fine imposed by the United States Department of Justice in 2023 for fixing prices on three of its drugs. The payment of this penalty will be made over a period of five years in installments of 22.5 million dollars annually plus 135 million dollars due in 2028.

Based in Tel Aviv, Teva is a company with 123 years of history whose star products are Copaxone, indicated for the treatment of multiple sclerosis, and Azilect, which combats the beginnings of Parkinson’s disease. With the first drug alone, the Israeli company achieved annual sales of 4.3 billion euros in 2016, a year after the end of the drug’s patent.

But the fact of wanting to maintain a dominant position in the distribution of Copaxone through abusive practices against distributors of the generic drug led the European Commission to initiate a formal process to sanction Teva. In July 2021, Juan Carlos Conde was appointed general director of the company for Spain and Portugal, replacing Carlos Teixeira, who retired at the same time.

__

(Featured image by  c1n3m4 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us